• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

成纤维细胞生长因子受体 4 在癌症中的作用。

Role of fibroblast growth factor receptor 4 in cancer.

机构信息

State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China.

出版信息

Cancer Sci. 2018 Oct;109(10):3024-3031. doi: 10.1111/cas.13759. Epub 2018 Oct 3.

DOI:10.1111/cas.13759
PMID:30070748
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6172014/
Abstract

Fibroblast growth factor receptors (FGFR) play a significant role in both embryonic development and in adults. Upon binding with ligands, FGFR signaling is activated and triggers various downstream signal cascades that are implicated in diverse biological processes. Aberrant regulations of FGFR signaling are detected in numerous cancers. Although FGFR4 was discovered later than other FGFR, information on the involvement of FGFR4 in cancers has significantly increased in recent years. In this review, the recent findings in FGFR4 structure, signaling transduction, physiological function, aberrant regulations, and effects in cancers as well as its potential applications as an anticancer therapeutic target are summarized.

摘要

成纤维细胞生长因子受体(FGFR)在胚胎发育和成人中都发挥着重要作用。与配体结合后,FGFR 信号被激活,并触发涉及多种生物过程的各种下游信号级联。在许多癌症中都检测到 FGFR 信号的异常调节。尽管 FGFR4 的发现晚于其他 FGFR,但近年来关于 FGFR4 与癌症的关系的信息显著增加。在这篇综述中,总结了 FGFR4 的结构、信号转导、生理功能、异常调节以及在癌症中的作用及其作为抗癌治疗靶点的潜在应用的最新发现。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c550/6172014/9f8acb9f4b22/CAS-109-3024-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c550/6172014/f0fe07eed2a7/CAS-109-3024-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c550/6172014/c37690d94f7a/CAS-109-3024-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c550/6172014/708a6584496c/CAS-109-3024-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c550/6172014/9f8acb9f4b22/CAS-109-3024-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c550/6172014/f0fe07eed2a7/CAS-109-3024-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c550/6172014/c37690d94f7a/CAS-109-3024-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c550/6172014/708a6584496c/CAS-109-3024-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c550/6172014/9f8acb9f4b22/CAS-109-3024-g004.jpg

相似文献

1
Role of fibroblast growth factor receptor 4 in cancer.成纤维细胞生长因子受体 4 在癌症中的作用。
Cancer Sci. 2018 Oct;109(10):3024-3031. doi: 10.1111/cas.13759. Epub 2018 Oct 3.
2
Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression.阻断 FGF19-FGFR4 轴以治疗性破坏癌症进展。
Curr Cancer Drug Targets. 2019;19(1):17-25. doi: 10.2174/1568009618666180319091731.
3
Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?成纤维细胞生长因子受体 4 是否是癌症治疗的合适靶点?
Curr Pharm Des. 2014;20(17):2881-98. doi: 10.2174/13816128113199990594.
4
Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies.成纤维细胞生长因子受体 4 在癌症中的靶向治疗:对机制和治疗策略的新认识。
Cells. 2019 Jan 9;8(1):31. doi: 10.3390/cells8010031.
5
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.首个用于治疗 FGFR4 信号通路激活的肝细胞癌的选择性 FGFR4 小分子抑制剂。
Cancer Discov. 2015 Apr;5(4):424-37. doi: 10.1158/2159-8290.CD-14-1029. Epub 2015 Mar 16.
6
FGFR4: A promising therapeutic target for breast cancer and other solid tumors.成纤维细胞生长因子受体 4:乳腺癌和其他实体瘤有前途的治疗靶点。
Pharmacol Ther. 2020 Oct;214:107590. doi: 10.1016/j.pharmthera.2020.107590. Epub 2020 May 31.
7
Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.成纤维细胞生长因子受体 4(FGFR4)选择性抑制剂作为肝细胞癌治疗药物:进展与展望。
J Med Chem. 2019 Mar 28;62(6):2905-2915. doi: 10.1021/acs.jmedchem.8b01531. Epub 2018 Nov 16.
8
Making way for suppressing the FGF19/FGFR4 axis in cancer.为抑制癌症中的 FGF19/FGFR4 轴铺平道路。
Future Med Chem. 2018 Oct;10(20):2457-2470. doi: 10.4155/fmc-2018-0099. Epub 2018 Oct 16.
9
FGF19- Signaling in Hepatocellular Carcinoma.成纤维细胞生长因子 19 在肝细胞癌中的信号转导作用。
Cells. 2019 Jun 4;8(6):536. doi: 10.3390/cells8060536.
10
Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.成纤维细胞生长因子受体4在肝细胞癌进展过程中调节细胞增殖、抗凋亡和甲胎蛋白分泌,是治疗干预的一个潜在靶点。
J Hepatol. 2009 Jan;50(1):118-27. doi: 10.1016/j.jhep.2008.08.015. Epub 2008 Oct 12.

引用本文的文献

1
Protective Effects of Regular Physical Activity: Differential Expression of , and Their Receptors in Trained and Untrained Individuals.规律体育活动的保护作用:训练有素者与未训练者体内 、 及其受体的差异表达
Int J Mol Sci. 2025 Jul 23;26(15):7115. doi: 10.3390/ijms26157115.
2
Therapeutic advances of targeting receptor tyrosine kinases in cancer.靶向治疗癌症受体酪氨酸激酶的治疗进展。
Signal Transduct Target Ther. 2024 Aug 14;9(1):201. doi: 10.1038/s41392-024-01899-w.
3
Oncofetal SNRPE promotes HCC tumorigenesis by regulating the FGFR4 expression through alternative splicing.

本文引用的文献

1
Molecular regulation of epithelial-to-mesenchymal transition in tumorigenesis (Review).肿瘤发生中上皮-间充质转化的分子调控(综述)。
Int J Mol Med. 2018 Mar;41(3):1187-1200. doi: 10.3892/ijmm.2017.3320. Epub 2017 Dec 13.
2
Germline variant FGFR4  p.G388R exposes a membrane-proximal STAT3 binding site.胚系变体 FGFR4  p.G388R 暴露出一个靠近细胞膜的 STAT3 结合位点。
Nature. 2015 Dec 24;528(7583):570-4. doi: 10.1038/nature16449. Epub 2015 Dec 16.
3
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
癌胚 SNRPE 通过选择性剪接调节 FGFR4 表达促进 HCC 肿瘤发生。
Br J Cancer. 2024 Jul;131(1):77-89. doi: 10.1038/s41416-024-02689-5. Epub 2024 May 25.
4
FGFR3 and FGFR4 overexpression in juvenile nasopharyngeal angiofibroma: impact of smoking history and implications for personalized management.成纤维细胞生长因子受体 3 和 4 在青少年鼻咽血管纤维瘤中的过表达:吸烟史的影响及其对个体化管理的意义。
J Appl Genet. 2023 Dec;64(4):749-758. doi: 10.1007/s13353-023-00780-w. Epub 2023 Sep 1.
5
FGF19-mediated ELF4 overexpression promotes colorectal cancer metastasis through transactivating FGFR4 and SRC.成纤维细胞生长因子 19(FGF19)介导的 E74 样因子 4(ELF4)过表达通过反式激活成纤维细胞生长因子受体 4(FGFR4)和 SRC 促进结直肠癌转移。
Theranostics. 2023 Feb 22;13(4):1401-1418. doi: 10.7150/thno.82269. eCollection 2023.
6
6-Amino-2,4,5-trimethylpyridin-3-ol and 2-amino-4,6-dimethylpyrimidin-5-ol derivatives as selective fibroblast growth factor receptor 4 inhibitors: design, synthesis, molecular docking, and anti-hepatocellular carcinoma efficacy evaluation.6-氨基-2,4,5-三甲基-3-吡啶醇和 2-氨基-4,6-二甲基-5-嘧啶醇衍生物作为选择性成纤维细胞生长因子受体 4 抑制剂的设计、合成、分子对接和抗肝癌疗效评价。
J Enzyme Inhib Med Chem. 2022 Dec;37(1):844-856. doi: 10.1080/14756366.2022.2048378.
7
Fibroblast growth factor receptor 4 as a prognostic indicator in triple-negative breast cancer.成纤维细胞生长因子受体4作为三阴性乳腺癌的预后指标
Transl Cancer Res. 2020 Nov;9(11):6881-6888. doi: 10.21037/tcr-20-1756.
8
Gly388Arg Polymorphism Reveals a Poor Prognosis, Especially in Asian Cancer Patients: A Meta-Analysis.Gly388Arg多态性显示预后不良,尤其是在亚洲癌症患者中:一项荟萃分析。
Front Oncol. 2021 Oct 19;11:762528. doi: 10.3389/fonc.2021.762528. eCollection 2021.
9
Molecular mechanisms of the anti-cancer drug, LY2874455, in overcoming the FGFR4 mutation-based resistance.抗癌药物 LY2874455 克服基于 FGFR4 突变的耐药性的分子机制。
Sci Rep. 2021 Aug 16;11(1):16593. doi: 10.1038/s41598-021-96159-0.
10
EPS364, a Novel Deep-Sea Bacterial Exopolysaccharide, Inhibits Liver Cancer Cell Growth and Adhesion.新型深海细菌胞外多糖EPS364可抑制肝癌细胞生长与黏附。
Mar Drugs. 2021 Mar 22;19(3):171. doi: 10.3390/md19030171.
首个用于治疗 FGFR4 信号通路激活的肝细胞癌的选择性 FGFR4 小分子抑制剂。
Cancer Discov. 2015 Apr;5(4):424-37. doi: 10.1158/2159-8290.CD-14-1029. Epub 2015 Mar 16.
4
Global cancer statistics, 2012.全球癌症统计数据,2012 年。
CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.
5
FGFR4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer.成纤维细胞生长因子受体 4 促进结直肠癌间质诱导的上皮-间充质转化。
Cancer Res. 2013 Oct 1;73(19):5926-35. doi: 10.1158/0008-5472.CAN-12-4718. Epub 2013 Aug 13.
6
FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancer.成纤维细胞生长因子受体 4 在结直肠癌细胞上皮-间充质转化中的作用及其治疗价值。
PLoS One. 2013 May 16;8(5):e63695. doi: 10.1371/journal.pone.0063695. Print 2013.
7
Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma.成纤维细胞生长因子受体在肺鳞癌中作为新兴治疗靶点的作用。
Future Oncol. 2013 Mar;9(3):377-86. doi: 10.2217/fon.12.190.
8
Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models.靶向 FGFR4 抑制临床前小鼠模型中的肝细胞癌。
PLoS One. 2012;7(5):e36713. doi: 10.1371/journal.pone.0036713. Epub 2012 May 15.
9
AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.AZD4547:一种口服生物利用度高、效力强且选择性的成纤维细胞生长因子受体酪氨酸激酶家族抑制剂。
Cancer Res. 2012 Apr 15;72(8):2045-56. doi: 10.1158/0008-5472.CAN-11-3034. Epub 2012 Feb 27.
10
Acetyl-CoA carboxylase 2-/- mutant mice are protected against fatty liver under high-fat, high-carbohydrate dietary and de novo lipogenic conditions.乙酰辅酶 A 羧化酶 2 基因敲除小鼠在高脂肪、高碳水化合物饮食和从头合成脂肪条件下可防止脂肪肝形成。
J Biol Chem. 2012 Apr 6;287(15):12578-88. doi: 10.1074/jbc.M111.309559. Epub 2012 Feb 23.